Medpace securities fraud class action
Analysis based on 9 articles · First reported May 19, 2026 · Last updated May 31, 2026
The class action lawsuit against Medpace could lead to a significant decline in its stock price due to potential financial penalties and damage to its reputation. Investors who purchased Medpace securities during the Class Period may experience losses, while the legal firm Bronstein, Gewirtz & Grossman, LLC stands to gain from a successful recovery.
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Medpace Holdings, Inc. and its officers, alleging violations of federal securities laws. The lawsuit claims that Medpace made materially false and misleading statements regarding its expected book-to-bill ratio for the fourth quarter and second half of fiscal year 2025, repeatedly portraying an overly optimistic ratio of approximately 1.15 despite contrary internal information. The Class Period for affected investors is between April 22, 2025, and February 9, 2026. Investors who suffered losses are encouraged to join the case, with a deadline of June 5, 2026, to request appointment as lead plaintiff. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, seeking reimbursement for expenses and attorneys' fees only if successful.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard